FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to a medical biotechnology. Disclosed is an immunogenic composition comprising polypeptides selected from the group consisting of amino acids represented in the group SEQ ID NO:2, SEQ ID NO:8, SEQ ID NO:15, SEQ ID NO:21 and combinations thereof. Proposed is a method for inducing an immunological response in a subject comprising administering said composition; and an isolated recombinant nucleic acid encoding a sapovirus VP1 protein, wherein the encoding nucleic acid comprises i) a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:14, SEQ ID NO:20 and combinations thereof.
EFFECT: invention enables to obtain immunogenic compositions containing immunogenic polypeptides of sapovirus, including immunogenic compositions containing antigens other than sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases.
12 cl, 2 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FMDV RECOMBINANT VACCINES AND USE THEREOF | 2015 |
|
RU2745373C2 |
| VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCTION OF ANTIBODY EXPRESSION | 2017 |
|
RU2813282C2 |
| METHOD OF INCREASING IMMUNOGENICITY OF PROTEIN/PEPTIDE ANTIGEN | 2021 |
|
RU2830627C1 |
| SUBUNIT VACCINE FOR TREATING OR PREVENTING RESPIRATORY TRACT INFECTION | 2020 |
|
RU2811991C2 |
| FIMH ESCHERICHIA COLI MUTANTS AND USE THEREOF | 2021 |
|
RU2831010C1 |
| VACCINES BASED ON VIRUS-LIKE PARTICLES (VLP) OF CANINE PARVOVIRUS (CPV) AND APPLICATION THEREOF | 2016 |
|
RU2710854C1 |
| CHIMERIC INFLUENZA VACCINES | 2021 |
|
RU2834969C1 |
| SELF-ASSEMBLED NANOSTRUCTURED VACCINES | 2019 |
|
RU2811439C2 |
| VACCINE AGAINST FELINE CALICIVIRUS | 2018 |
|
RU2792898C2 |
| RECOMBINANT VECTORS EXPRESSING AVIAN INFLUENZA VIRUS ANTIGENS AND APPLICATIONS THEREOF | 2017 |
|
RU2761869C2 |
